Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 8/20 | 0.68 |
| ▸ | MC1R | Q01726 | 5/20 | 0.68 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.54 |
| ▸ | TUBB | P07437 | 2/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.54 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.54 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.54 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.54 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.54 |
| ▸ | F12 | P00748 | 4/20 | 0.51 |
| ▸ | MC5R | P33032 | 1/20 | 0.51 |
| ▸ | MC3R | P41968 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12657700 | 0.97 | MC4R (0.64) | MC4RMC1RTUBB4ATUBBTUBA3C | |
| SCHEMBL12657695 | 0.97 | MC4R (0.73) | MC4RMC1RTUBB4ATUBBTUBA3C | |
| SCHEMBL21392375 | 0.97 | MC4R (0.72) | MC4RMC1RTUBB4ATUBBTUBA3C | |
| SCHEMBL12092570 | 0.97 | MC4R (0.72) | MC4RMC1RTUBB4ATUBBTUBA3C | |
| SCHEMBL12092708 | 0.96 | MC4R (0.69) | MC4RMC1RTUBB4ATUBBTUBA3C | |
| SCHEMBL21392465 | 0.96 | MC4R (0.69) | MC4RMC1RTUBB4ATUBBTUBA3C | |
| SCHEMBL21392463 | 0.96 | MC4R (0.69) | MC4RMC1RTUBB4ATUBBTUBA3C | |
| SCHEMBL20206275 | 0.96 | MC4R (0.69) | MC4RMC1RTUBB4ATUBBTUBA3C | |
| SCHEMBL12092627 | 0.96 | MC4R (0.69) | MC4RMC1RTUBB4ATUBBTUBA3C | |
| SCHEMBL21392260 | 0.96 | MC4R (0.69) | MC4RMC1RTUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | PALATIN TECHNOLOGIES INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | PALATIN TECHNOLOGIES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10017539-B2 | Melanocortin-1 receptor-specific cyclic hexapeptides | PALATIN TECHNOLOGIES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | PALATIN TECHNOLOGIES INC (US) | 2018-05-31 | — | — | US | disclosed |
| US-20170008931-A1 | Melanocortin-1 Receptor-Specific Cyclic Hexapeptides | PALATIN TECHNOLOGIES INC (US) | 2017-01-12 | — | — | US | disclosed |
| US-9447148-B2 | Melanocortin-1 receptor-specific cyclic peptides | PALATIN TECHNOLOGIES, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150038434-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES INC (US) | 2015-02-05 | — | — | US | disclosed |
| US-8877890-B2 | Melanocortin-1 receptor-specific cyclic peptides | PALATIN TECHNOLOGIES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130296256-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-8492517-B2 | Melanocortin-1 receptor-specific cyclic peptides | PALATIN TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| WO-2011063366-A1 | MELANOCORTIN-1 RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | MC1R, MC3R, MC4R | MC4R 3/4885MC1R 1/4885TUBB4A 3433/4885 |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | MC4R 6/4885MC1R 2/4885TUBB4A 4234/4885 |
| US-10017539-B2 | Melanocortin-1 receptor-specific cyclic hexapeptides | MC1R, MC3R, MC5R | MC4R 4/4885MC1R 1/4885TUBB4A 4844/4885 |
| US-20150038434-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | MC1R, MC3R, MC5R | MC4R 4/4885MC1R 1/4885TUBB4A 4704/4885 |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | MC3R, MC1R, MC2R | MC4R 6/4885MC1R 2/4885TUBB4A 4234/4885 |
| US-20170008931-A1 | Melanocortin-1 Receptor-Specific Cyclic Hexapeptides | MC1R, MC3R, MC5R | MC4R 4/4885MC1R 1/4885TUBB4A 4844/4885 |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | MC1R, MC3R, MC4R | MC4R 3/4885MC1R 1/4885TUBB4A 3433/4885 |
| US-20130296256-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | MC1R, MC3R, MC5R | MC4R 4/4885MC1R 1/4885TUBB4A 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.